LGND Valuation
Ligand Pharmaceuticals Inc
$
154.270
- Overview
- Forecast
- Valuation
- Earnings
LGND Relative Valuation
LGND's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, LGND is overvalued; if below, it's undervalued.
Historical Valuation
Ligand Pharmaceuticals Inc (LGND) is now in the Undervalued zone, suggesting that its current forward PS ratio of 12.65 is considered Undervalued compared with the five-year average of -9.43. The fair price of Ligand Pharmaceuticals Inc (LGND) is between 213.02 to 252.97 according to relative valuation methord. Compared to the current price of 152.69 USD , Ligand Pharmaceuticals Inc is Undervalued By 28.32%.
Relative Value
Fair Zone
213.02-252.97
Current Price：152.69
28.32%
Undervalued
48.07
PE
1Y
3Y
5Y
Trailing
Forward
18.64
EV/EBITDA
Ligand Pharmaceuticals Inc. (LGND) has a current EV/EBITDA of 18.64. The 5-year average EV/EBITDA is 17.63. The thresholds are as follows: Strongly Undervalued below 4.94, Undervalued between 4.94 and 11.29, Fairly Valued between 23.98 and 11.29, Overvalued between 23.98 and 30.33, and Strongly Overvalued above 30.33. The current Forward EV/EBITDA of 18.64 falls within the Historic Trend Line -Fairly Valued range.
35.31
EV/EBIT
Ligand Pharmaceuticals Inc. (LGND) has a current EV/EBIT of 35.31. The 5-year average EV/EBIT is -89.11. The thresholds are as follows: Strongly Undervalued below -705.12, Undervalued between -705.12 and -397.12, Fairly Valued between 218.89 and -397.12, Overvalued between 218.89 and 526.89, and Strongly Overvalued above 526.89. The current Forward EV/EBIT of 35.31 falls within the Historic Trend Line -Fairly Valued range.
12.65
PS
Ligand Pharmaceuticals Inc. (LGND) has a current PS of 12.65. The 5-year average PS is 10.18. The thresholds are as follows: Strongly Undervalued below 6.04, Undervalued between 6.04 and 8.11, Fairly Valued between 12.25 and 8.11, Overvalued between 12.25 and 14.31, and Strongly Overvalued above 14.31. The current Forward PS of 12.65 falls within the Overvalued range.
22.96
P/OCF
Ligand Pharmaceuticals Inc. (LGND) has a current P/OCF of 22.96. The 5-year average P/OCF is 9.34. The thresholds are as follows: Strongly Undervalued below -7.79, Undervalued between -7.79 and 0.78, Fairly Valued between 17.91 and 0.78, Overvalued between 17.91 and 26.47, and Strongly Overvalued above 26.47. The current Forward P/OCF of 22.96 falls within the Overvalued range.
41.93
P/FCF
Ligand Pharmaceuticals Inc. (LGND) has a current P/FCF of 41.93. The 5-year average P/FCF is 6.48. The thresholds are as follows: Strongly Undervalued below -251.36, Undervalued between -251.36 and -122.44, Fairly Valued between 135.40 and -122.44, Overvalued between 135.40 and 264.32, and Strongly Overvalued above 264.32. The current Forward P/FCF of 41.93 falls within the Historic Trend Line -Fairly Valued range.
Ligand Pharmaceuticals Inc (LGND) has a current Price-to-Book (P/B) ratio of 3.44. Compared to its 3-year average P/B ratio of 2.08 , the current P/B ratio is approximately 65.91% higher. Relative to its 5-year average P/B ratio of 2.28, the current P/B ratio is about 50.97% higher. Ligand Pharmaceuticals Inc (LGND) has a Forward Free Cash Flow (FCF) yield of approximately 1.86%. Compared to its 3-year average FCF yield of 5.48%, the current FCF yield is approximately -66.05% lower. Relative to its 5-year average FCF yield of 4.52% , the current FCF yield is about -58.80% lower.
3.44
P/B
Median3y
2.08
Median5y
2.28
1.86
FCF Yield
Median3y
5.48
Median5y
4.52
Competitors Valuation Multiple
The average P/S ratio for LGND's competitors is 48.52, providing a benchmark for relative valuation. Ligand Pharmaceuticals Inc Corp (LGND) exhibits a P/S ratio of 12.65, which is -73.93% above the industry average. Given its robust revenue growth of 14.68%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of LGND increased by 44.32% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -15.47 to -36.78.
The secondary factor is the Revenue Growth, contributed 14.68%to the performance.
Overall, the performance of LGND in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
MTRN
Materion Corp
110.645
USD
+0.46%
WOR
Worthington Enterprises Inc
66.710
USD
+2.61%
GBX
Greenbrier Companies Inc
47.560
USD
+1.67%
CNMD
Conmed Corp
55.580
USD
+2.91%
RAMP
Liveramp Holdings Inc
25.880
USD
-0.08%
VERA
Vera Therapeutics Inc
22.420
USD
+6.05%
SUPN
Supernus Pharmaceuticals Inc
42.860
USD
+3.93%
VSEC
VSE Corp
162.780
USD
-1.29%
ZGN
Ermenegildo Zegna NV
8.180
USD
+3.28%
SEI
Solaris Energy Infrastructure Inc
27.790
USD
-9.36%
FAQ
Is Ligand Pharmaceuticals Inc (LGND) currently overvalued or undervalued?
Ligand Pharmaceuticals Inc (LGND) is now in the Undervalued zone, suggesting that its current forward PS ratio of 12.65 is considered Undervalued compared with the five-year average of -9.43. The fair price of Ligand Pharmaceuticals Inc (LGND) is between 213.02 to 252.97 according to relative valuation methord. Compared to the current price of 152.69 USD , Ligand Pharmaceuticals Inc is Undervalued By 28.32% .
What is Ligand Pharmaceuticals Inc (LGND) fair value?
How does LGND's valuation metrics compare to the industry average?
What is the current P/B ratio for Ligand Pharmaceuticals Inc (LGND) as of Aug 13 2025?
What is the current FCF Yield for Ligand Pharmaceuticals Inc (LGND) as of Aug 13 2025?
What is the current Forward P/E ratio for Ligand Pharmaceuticals Inc (LGND) as of Aug 13 2025?